Charles Schwab
THRD

Charles Schwab’s Third Harmonic Bio THRD Stock Holding History

Charles Schwab’s Portfolio THRD Stock Details THRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-185,797
Closed -$1.01M – 3541
2025
Q2 		$1.01M Buy
185,797
+8,632
+5% +$43K ﹤0.01% 2896
2025
Q1 		$615K Buy
177,165
+3,966
+2% +$19.2K ﹤0.01% 3007
2024
Q4 		$1.78M Buy
173,199
+30,611
+21% +$381K ﹤0.01% 2713
2024
Q3 		$1.93M Buy
142,588
+5,126
+4% +$63.5K ﹤0.01% 2716
2024
Q2 		$1.79M Buy
137,462
+6,857
+5% +$84.8K ﹤0.01% 2738
2024
Q1 		$1.23M Buy
130,605
+2,350
+2% +$22.8K ﹤0.01% 2728
2023
Q4 		$1.41M Buy
128,255
+1,400
+1% +$11.1K ﹤0.01% 2718
2023
Q3 		$811K Buy
126,855
+23,585
+23% +$144K ﹤0.01% 2867
2023
Q2 		$497K Buy
103,270
+16,492
+19% +$78.5K ﹤0.01% 3056
2023
Q1 		$358K Sell
86,778
-777
-0.9% -$3.3K ﹤0.01% 3050
2022
Q4 		$376K Buy
+87,555
New +$1.47M ﹤0.01% 3064

Other funds holding THRD

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AB
Amalgamated Bank New York $13.1B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Charles Schwab's THRD Position: Q3 2025 in Review

Charles Schwab sold out of Third Harmonic Bio (THRD) in Q3 2025, closing a stake of 185,797 shares — an estimated $1.01M sold.

Charles Schwab first reported a position in THRD in Q4 2022 and held it in 11 quarters. The position peaked at $1.93M in Q3 2024. 18 funds tracked by Wall St. Rank hold THRD as of Q3 2025.

  • Charles Schwab reported no remaining Third Harmonic Bio position as of Q3 2025 after selling out during the quarter.
  • Charles Schwab sold 185,797 Third Harmonic Bio shares in Q3 2025, an estimated $1.01M.
  • Charles Schwab first reported a position in Third Harmonic Bio in Q4 2022 and held it in 11 quarters.
  • Charles Schwab's Third Harmonic Bio position peaked at $1.93M in Q3 2024.
  • 18 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q3 2025.

Based on Charles Schwab's 13F filing for Q3 2025, filed 10 Nov 2025.